eli lilly and company zepbound - Search News

News

Eli Lilly, weight loss and Daily Pill

CBS News on MSN · 7h

GLP-1 pill shows success for diabetes, weight loss, Eli Lilly says

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for diabetes and weight loss.

The New York Times · 6h

What to Know About Eli Lilly’s Daily Pill for Weight Loss

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

USA TODAY on MSN · 10h

Eli Lilly announces trial results of new weight loss, diabetes pill; stock booms

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

9h

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

10hon MSN

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

8h

Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results